Skip to Main Content

Author Details

Tarek A Bismar
University of Calgary Cumming School of Medicine, Rockyview General Hospital
2002
128
38
PMIDPaper TitleJournal TitlePublished Year
36259569Investigation of androgen receptor-dependent alternative splicing has identified a unique subtype of lethal prostate cancer.Asian J Androl2023
37629142Cleavage and Polyadenylation-Specific Factor 4 (CPSF4) Expression Is Associated with Enhanced Prostate Cancer Cell Migration and Cell Cycle Dysregulation, In Vitro.Int J Mol Sci2023
37627171Editorial: The Application of Proteogenomics to Urine Analysis for the Identification of Novel Biomarkers of Prostate Cancer: An Exploratory Study.Cancers (Basel)2023
37424308Disparities in prostate cancer screening, diagnoses, management, and outcomes between Indigenous and non-Indigenous men in a universal health care system.Cancer2023
37345203Serrate RNA Effector Molecule (SRRT) Is Associated with Prostate Cancer Progression and Is a Predictor of Poor Prognosis in Lethal Prostate Cancer.Cancers (Basel)2023
37047027<i>Downregulation of BUD31</i> Promotes Prostate Cancer Cell Proliferation and Migration via Activation of p-AKT and Vimentin In Vitro.Int J Mol Sci2023
37370778Large, Nested Variant of Urothelial Carcinoma Is Enriched with Activating Mutations in Fibroblast Growth Factor Receptor-3 among Other Targetable Mutations.Cancers (Basel)2023
36901698Glycyl-tRNA Synthetase (GARS) Expression Is Associated with Prostate Cancer Progression and Its Inhibition Decreases Migration, and Invasion In Vitro.Int J Mol Sci2023
35982181Loss of KLK4::KLKP1 pseudogene expression by RNA chromogenic in-situ hybridization is associated with PTEN loss and increased risk of biochemical recurrence in a cohort of middle eastern men with prostate cancer.J Cancer Res Clin Oncol2023
34643090Patients with Muscle-Invasive Bladder Cancer with Nonluminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy.J Urol2022
35563163The Expression of Proto-Oncogene <i>ETS-Related Gene</i> (<i>ERG</i>) Plays a Central Role in the Oncogenic Mechanism Involved in the Development and Progression of Prostate Cancer.Int J Mol Sci2022
36362115The Association between Cyclin Dependent Kinase 2 Associated Protein 1 (CDK2AP1) and Molecular Subtypes of Lethal Prostate Cancer.Int J Mol Sci2022
35163398ARPC1B Is Associated with Lethal Prostate Cancer and Its Inhibition Decreases Cell Invasion and Migration In Vitro.Int J Mol Sci2022
33398501[Molecular pathology of urogenital tumors : Recommendations from the 2019 International Society of Urological Pathology (ISUP) Consensus Conference].Pathologe2021
33771697Mapping Isoform Abundance and Interactome of the Endogenous TMPRSS2-ERG Fusion Protein by Orthogonal Immunoprecipitation-Mass Spectrometry Assays.Mol Cell Proteomics2021
33864110Expression of ISL1 and its partners in prostate cancer progression and neuroendocrine differentiation.J Cancer Res Clin Oncol2021
34068856Copy Number Profiles of Prostate Cancer in Men of Middle Eastern Ancestry.Cancers (Basel)2021
34337539Decreased ATM Protein Expression Is Substantiated with PTEN Loss in Defining Aggressive Phenotype of Prostate Cancer Associated with Lethal Disease.Eur Urol Open Sci2021
31455846Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance.Prostate Cancer Prostatic Dis2020
35050780Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate.JCO Precis Oncol2020
34337483High Serine-arginine Protein Kinase 1 Expression with PTEN Loss Defines Aggressive Phenotype of Prostate Cancer Associated with Lethal Outcome and Decreased Overall Survival.Eur Urol Open Sci2020
31812633Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy.Urol Oncol2020
32044806Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer.Am J Surg Pathol2020
32576165DNA methylation signatures of Prostate Cancer in peripheral T-cells.BMC Cancer2020
32520708Case - Highly aggressive urothelial carcinoma of the bladder presenting with solitary metastasis to the phalanx.Can Urol Assoc J2020
32238875Clonal evaluation of prostate cancer molecular heterogeneity in biopsy samples by dual immunohistochemistry and dual RNA in situ hybridization.Mod Pathol2020
32350606Molecular characterization of prostate cancer in Middle Eastern population highlights differences with Western populations with prognostic implication.J Cancer Res Clin Oncol2020
31584209Clonal evaluation of early onset prostate cancer by expression profiling of ERG, SPINK1, ETV1, and ETV4 on whole-mount radical prostatectomy tissue.Prostate2020
30542054Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance.Prostate Cancer Prostatic Dis2019
31206668Development of a predictive model for stromal content in prostate cancer samples to improve signature performance.J Pathol2019
31129769Combined loss of TFF3 and PTEN is associated with lethal outcome and overall survival in men with prostate cancer.J Cancer Res Clin Oncol2019
31125117Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma.Int J Cancer2019
29511883Validation of a 10-gene molecular signature for predicting biochemical recurrence and clinical metastasis in localized prostate cancer.J Cancer Res Clin Oncol2018
30165429Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease.Carcinogenesis2018
30101374Clinical utility of assessing PTEN and ERG protein expression in prostate cancer patients: a proposed method for risk stratification.J Cancer Res Clin Oncol2018
29904055Quantitative in vivo whole genome motility screen reveals novel therapeutic targets to block cancer metastasis.Nat Commun2018
27738792SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion.Pathol Oncol Res2017
28265591Tubulovillous Adenoma in the Bladder in a Dual Pancreas-Kidney Transplant Patient.J Endourol Case Rep2017
28511652ING3 promotes prostate cancer growth by activating the androgen receptor.BMC Med2017
28786877Eosinophilic Solid and Cystic Renal Cell Carcinoma (ESC RCC): Further Morphologic and Molecular Characterization of ESC RCC as a Distinct Entity.Am J Surg Pathol2017
26725250SPINK1 expression in relation to PTEN and ERG in matched primary and lymph node metastatic prostate cancer: Implications for biomarker development.Urol Oncol2016
27819326Insights into a novel nuclear function for Fascin in the regulation of the amino-acid transporter SLC3A2.Sci Rep2016
27271990High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer.Tumour Biol2016
27534968Ankyrin G expression is associated with androgen receptor stability, invasiveness, and lethal outcome in prostate cancer patients.J Mol Med (Berl)2016
26803516ING3 is associated with increased cell invasion and lethal outcome in ERG-negative prostate cancer patients.Tumour Biol2016
26711283ERG expression in prostate cancer: biological relevance and clinical implication.J Cancer Res Clin Oncol2016
26907180microRNA 338-3p exhibits tumor suppressor role and its down-regulation is associated with adverse clinical outcome in prostate cancer patients.Mol Biol Rep2016
26795349Neural Cell Adhesion Protein CNTN1 Promotes the Metastatic Progression of Prostate Cancer.Cancer Res2016
25517865ERG Expression in Prostate Needle Biopsy: Potential Diagnostic and Prognostic Implications.Appl Immunohistochem Mol Morphol2015
25819753ING3 protein expression profiling in normal human tissues suggest its role in cellular growth and self-renewal.Eur J Cell Biol2015
  • 1 - 50 of 128

Recommended Authors

Institute of Pathology, University Medical Center Hamburg-Eppendorf
Career Start Year 2012
Number of shared co-authors 2
Erasmus Medical Center
Career Start Year 2011
Number of shared co-authors 9
Queen's University
Career Start Year 2010
Number of shared co-authors 11
National Cancer Institute
Career Start Year 2010
Number of shared co-authors 15
Michigan Center for Translational Pathology, University of Michigan ann arbor
Career Start Year 2007
Number of shared co-authors 29
Institute for Pathology, University Hospital Schleswig-Holstein
Career Start Year 2007
Number of shared co-authors 17
Centre hospitalier de l'Universite de Montreal
Career Start Year 2006
Number of shared co-authors 10
Institute of Pathology, University Medical Center Hamburg-Eppendorf
Career Start Year 2006
Number of shared co-authors 3
Fred Hutchinson Cancer Center
Career Start Year 2005
Number of shared co-authors 32
Biomedicine Discovery Institute, Monash University
Career Start Year 2005
Number of shared co-authors 10
Charite - University Hospital Berlin
Career Start Year 2004
Number of shared co-authors 19
University of British Columbia
Career Start Year 2004
Number of shared co-authors 24
Institute of Cancer Research
Career Start Year 2004
Number of shared co-authors 5
Weill Cornell Medical College
Career Start Year 2003
Number of shared co-authors 34
Cambridge University Hospitals National Health Service Foundation Trust
Career Start Year 2003
Number of shared co-authors 23
University of British Columbia
Career Start Year 2002
Number of shared co-authors 29
Fred Hutchinson Cancer Center
Career Start Year 2001
Number of shared co-authors 35
University of British Columbia
Career Start Year 2000
Number of shared co-authors 47
Duke University School of Medicine
Career Start Year 2000
Number of shared co-authors 28
Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center
Career Start Year 2000
Number of shared co-authors 41
Centre de Recherche du CHU de Quebec-Universite Laval (axe Oncologie)
Career Start Year 1999
Number of shared co-authors 19
University College London
Career Start Year 1999
Number of shared co-authors 10
Erasmus MC Cancer Institute, University Medical Center
Career Start Year 1998
Number of shared co-authors 18
Institute of Pathology, University Medical Center Hamburg-Eppendorf
Career Start Year 1997
Number of shared co-authors 2
Institute of Pathology, University Medical Center Hamburg-Eppendorf
Career Start Year 1996
Number of shared co-authors 10
Royal Melbourne Hospital, The University of Melbourne
Career Start Year 1989
Number of shared co-authors 11
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 1987
Number of shared co-authors 32
Skane University Hospital, Lund University
Career Start Year 1987
Number of shared co-authors 32
Institut du cancer de Montreal
Career Start Year 1985
Number of shared co-authors 22
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 1982
Number of shared co-authors 12

Collaborators

University of Bern
Co-authored papers 15
University of Miami Miller School of Medicine/Sylvester Comprehensive Cancer Center
Co-authored papers 13
Cross Cancer Institute
Co-authored papers 12
Vattikuti Urology Institute
Co-authored papers 11
Cumming School of Medicine, University of Calgary
Co-authored papers 9
Veracyte Inc.
Co-authored papers 9
University of Sao Paulo
Co-authored papers 7
University of Michigan Medical School.
Co-authored papers 7
Yale University School of Medicine
Co-authored papers 6
Segal Cancer Centre, Jewish General Hospital
Co-authored papers 6
McGill University Health Centre, McGill University
Co-authored papers 6
University of California
Co-authored papers 5
Co-authored papers 5
University of Trento
Co-authored papers 5
Faculty of Pharmacy, Suez Canal University
Co-authored papers 5
University of British Columbia
Co-authored papers 4
Caryl and Israel Englander Institute for Precision Medicine
Co-authored papers 4
Princess Margaret Cancer Center, University Health Network.
Co-authored papers 4
Johns Hopkins University School of Medicine
Co-authored papers 4
University of California los angeles
Co-authored papers 4
Rogel Cancer Center, University of Michigan Medical School ann arbor
Co-authored papers 3
GenomeDx Biosciences Inc.
Co-authored papers 3
GenomeDx Biosciences Inc.
Co-authored papers 3
UCSF Medical Center-Mount Zion
Co-authored papers 3
Co-authored papers 3
University of Alabama at Birmingham, USA O'Neal Comprehensive Cancer Center
Co-authored papers 3
Weill Medical College of Cornell University
Co-authored papers 3
Vanderbilt University Medical Center
Co-authored papers 3
Veracyte inc.
Co-authored papers 3
University of Montreal Health Center
Co-authored papers 3